




EluPro™

Antibiotic-Eluting BioEnvelope

Feel the difference biology makes.

The first and only FDA cleared antibiotic-eluting bioenvelope for cardiac implantable electronic devices.



EluPro™

Antibiotic-Eluting BioEnvelope

Better Together

Trusted antibiotics¹⁻³

Rifampin and minocycline to prevent bacterial colonization

Proven benefits of a natural, biologic material⁴⁻⁵

Supports the formation of healthy vascularized tissue



**The power of
regenerative medicine —
the biomatrix and local antibiotic
delivery together —
for a better implant experience.**



What the Experts Say

A Long-Term Healthy Pocket: The Ultimate Goal

"When I implant a pacemaker or defibrillator, minimizing the risk of any future complications is critical. EluPro combines the remodeling properties of regenerative medicine through extracellular matrix, along with long-acting antibiotic delivery to create a healthy environment for every device implantation."

Benjamin D'Souza, MD, FACC, FHRS

Trusted Antibiotics

With rifampin and minocycline at its core, EluPro delivers trusted antibiotic protection. This synergistic combination ensures broad-spectrum coverage against potential pathogens, including the gram-positive bacteria associated with CIED infections.^{1,2}


Protection from bacterial colonization

EluPro, in preclinical testing, successfully eliminated bacterial colonization, thus reducing the potential for infection.^{3,6-7}

Local, extended-release antibiotic delivery

Antibiotic protection at the implant site for an extended period post-implant — when infection risk is elevated — without relying on high systemic doses of antibiotics.

Pharmacokinetic preclinical studies have shown antibiotic release for at least a week, with laboratory testing indicating antibiotic activity persists throughout the *in vivo* drug release profile.³



100%
Bacterial Kill

In vivo and *in vitro* studies.³

Proven Benefits of Biomatrix

The biomatrix in bioenvelopes leverages advanced tissue engineering to improve biocompatibility between the device and patient. It supports the formation of healthy tissue and aids in facilitating reoperative procedures.^{4,8-9}



Soft feel and natural lubricity

Conforms to the shape of the CIED and provides immediate and long-term device stability.^{4,8}



Supports natural biologic healing

Reduces foreign-body response, which mitigates inflammation and fosters vascularization and integration.⁴⁻⁵




Creates a stable pocket environment

Securely holds the CIED, reducing the likelihood of complications such as migration or erosion.¹⁰

The HEAL Study

In the HEAL clinical study of device changeouts, the BioEnvelope was shown to promote the regeneration of healthy, vascularized tissue around CIEDs, highlighting the benefits of a bioenvelope.^{4,8}


Physicians scored bioenvelope lead adhesions as **less severe** ($p < .05$), and reoperations as **less difficult** ($p < .05$).



BioEnvelope Patient

Vascularized, healthy-tissue pocket

Pro-Remodeling Response




No-Envelope Patient

Fibrotic tissue


Chronic Inflammatory Response

Ordering Information

Shown actual size




EluPro BioEnvelope
Size 2
6.9cm x 6.5cm
BE02





EluPro BioEnvelope
Size 3
6.9cm x 8.0cm
BE03


EluPro™ Implant Technique

EluPro's easy-to-use format fits your implantation procedure

- 

1. To use, select the appropriate size EluPro for the CIED. Handle the sterile bioenvelope using aseptic technique.
- 

2. Hydrate EluPro by immersing it completely in sterile solution (e.g. saline, water) for 1-2 minutes.
- 

3. Slide the CIED into EluPro, with lead wires emerging out of the opening. Secure the bioenvelope with one stitch.
- 

4. Implant the CIED with the bioenvelope into the pocket and secure it to the fascia as per standard practice.

1. Chemaly RF, et al. *Int J Infect Dis*. 2010;14:e548–e552. doi:10.1016/j.ijid.2009.08.007
2. Sohail MR, et al. *J Am Coll Cardiol*. 2007;49:1851–1859. doi:10.1016/j.jacc.2007.01.072
3. Garrigos ZE, et al. *Front Drug Deliv*. 2024;4:1441956. doi:10.3389/fddev.2024.1441956
4. Catanzaro JN, et al. *Front Cardiovasc Med*. 2025;12:1638929. doi:10.3389/fcvm.2025.1638929
5. Deegan D, et al. *J Regen Med*. 2022;11:5. doi:10.4172/2325-9620.1000226
6. Büttner H, et al. *Front Cell Infect Microbiol*. 2015;5:14. doi:10.3389/fcimb.2015.00014
7. Turtiainen J, et al. *Eur J Vasc Endovasc Surg*. 2014;47:411–417. doi:10.1016/j.ejvs.2013.12.025
8. Catanzaro JN, et al. *Heart Rhythm*. 2023;20(5):S712–S713. doi:10.1016/j.hrthm.2023.03.1478
9. Srivastava A, Nayak HM. *HeartRhythm Case Rep*. 2023;9:797–799. doi:10.1016/j.hrcr.2023.08.007
10. EluPro IFU



EluPro™ Antibiotic-Eluting BioEnvelope
Indications, Safety, and Warnings
<https://qrco.de/bgcGyo>

Caution: Federal Law (U.S.) restricts this device to sale by or on the order of a licensed medical practitioner. For full prescribing information, including indications, contraindications, warnings, and precautions, refer to the Instructions For Use (IFU).

**Boston
Scientific**
Advancing science for life™

Cardiology
300 Boston Scientific Way
Marlborough, MA 01752-1234
www.bostonscientific.com

Medical Professionals:
1.800.CARDIAC (227.3422)
Customer Service:
1.888.272.1001

© 2026 Boston Scientific Corporation
or its affiliates. All rights reserved.

CRM-2145209-AC